Aktienanalyse zu Ardelyx, Inc. (ARDX)ARDXArdelyx, Inc.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. The Company markets two therapies from the active ingredient tenapanor, a sodium/hydrogen exchanger (NHE3) inhibitor. Tenapanor, branded as IBSRELA, is approved in the United States for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Tenapanor, branded as XPHOZAH, is approved in the United States to reduce serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy. It is also developing a next-generation NHE3 inhibitor, RDX10531, which has demonstrated in preclinical models to have improved solubility and potency compared to tenapanor. RDX10531 has applications across multiple therapeutic areas. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $3.81 and the RSI at 32.281, which indicates that the stock is oversold, it may seem attractive. However, the significant risk is highlighted by the recent 40.47% decline over the past year and the loss of Medicare appeal for Xphozah, which could severely impact future revenues. Therefore, while there may be potential for recovery, the current market sentiment and insider selling trends suggest that now is not the right time to buy.

7 analysts cover ARDX: 7 rate it Buy, 0 Hold and 0 Sell. The average price target is 14.86.